Disease · MONDO_0007079
Comparisons in its trials189
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 189
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nalmefene 18.06 mg vs Placebo: serious adverse events | 7 of 341 | 14 of 337 | 678 | NCT00812461 | Trial comparisons |
| Nalmefene 18.06 mg vs Placebo: serious adverse events | 35 of 501 | 8 of 164 | 665 | NCT00811941 | Trial comparisons |
| Nalmefene 18.06 mg vs Placebo: serious adverse events | 17 of 302 | 18 of 296 | 598 | NCT00811720 | Trial comparisons |
| Medisorb Naltrexone 380 mg (VIVITROL) vs Oral Naltrexone 50 mg: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study | 336 of 371 | 53 of 65 | 436 | NCT01218997 | Trial comparisons |
| Medisorb Naltrexone 380 mg (VIVITROL) vs Oral Naltrexone 50 mg: serious adverse events | 49 of 371 | 5 of 65 | 436 | NCT01218997 | Trial comparisons |
| LY2196044 vs Placebo: Number of Participants With Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)≥10 at Any Time From Baseline Through Week 16 Endpoint | 0 of 187 | 0 of 188 | 375 | NCT00804570 | Trial comparisons |
| LY2196044 vs Placebo: serious adverse events | 4 of 187 | 5 of 188 | 375 | NCT00804570 | Trial comparisons |
| Sugar Pill vs Gabapentin Enacarbil: deaths from any cause | 0 of 168 | 1 of 170 | 338 | NCT02252536 | Trial comparisons |
| Sugar Pill vs Gabapentin Enacarbil: serious adverse events | 6 of 168 | 8 of 170 | 338 | NCT02252536 | Trial comparisons |
| Medisorb Naltrexone 380 mg vs Medisorb Naltrexone 190 mg: Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While in Study | 143 of 175 | 130 of 157 | 332 | NCT01218971 | Trial comparisons |
| VIVITROL 380 mg (Double-blind Period) vs Placebo for VIVITROL 380 mg (Double-blind Period): serious adverse events | 29 of 152 | 27 of 148 | 300 | NCT00501631 | Trial comparisons |
| Sugar Pill vs Gabapentin Enacarbil: Percentage of Subjects Abstinent From Alcohol (Key Secondary Endpoint) | 16 of 136 | 17 of 146 | 282 | NCT02252536 | Trial comparisons |
| Sugar Pill vs Gabapentin Enacarbil: Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 1-level | 107 of 134 | 115 of 146 | 280 | NCT02252536 | Trial comparisons |
| Sugar Pill vs Gabapentin Enacarbil: Percentage of Subjects With a World Health Organization (WHO) Drinking Risk Category Decrease of at Least 2-levels | 69 of 134 | 80 of 146 | 280 | NCT02252536 | Trial comparisons |
| Phase 1 Liberal Response vs Phase 1 Stringent Response: Count of Responders and Non-responders in Phase 1 | 103 of 127 | 80 of 123 | 250 | NCT00115037 | Trial comparisons |
| Extended-release Injectable Naltrexone (XR-NTX) vs Oral Naltrexone (PO-NTX): deaths from any cause | 2 of 123 | 3 of 125 | 248 | NCT02478489 | Trial comparisons |
| Extended-release Injectable Naltrexone (XR-NTX) vs Oral Naltrexone (PO-NTX): serious adverse events | 43 of 123 | 43 of 125 | 248 | NCT02478489 | Trial comparisons |
| XR-NTX vs Oral Naltrexone: deaths from any cause | 2 of 117 | 0 of 120 | 237 | NCT01893827 | Trial comparisons |
| XR-NTX vs Oral Naltrexone: serious adverse events | 22 of 117 | 20 of 120 | 237 | NCT01893827 | Trial comparisons |
| Quetiapine Fumerate Plus Medical Management vs Sugar Pill Plus Medical Management: Percent Subjects With no Heavy Drinking Day | 17 of 105 | 24 of 113 | 218 | NCT00498628 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007079/comparisons